Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
104.09
+1.99 (1.95%)
Apr 9, 2026, 4:00 PM EDT - Market closed
Protagonist Therapeutics Revenue
In the year 2025, Protagonist Therapeutics had annual revenue of $46.02M, down -89.41%. Protagonist Therapeutics had revenue of $7.44M in the quarter ending December 31, 2025, a decrease of -95.64%.
Revenue (ttm)
$46.02M
Revenue Growth
-89.41%
P/S Ratio
144.33
Revenue / Employee
$348,606
Employees
132
Market Cap
6.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.02M | -388.42M | -89.41% |
| Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
| Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
| Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
| Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
| Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
| Dec 31, 2019 | 231.00K | -30.69M | -99.25% |
| Dec 31, 2018 | 30.93M | 10.86M | 54.14% |
| Dec 31, 2017 | 20.06M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.40B |
| Mirum Pharmaceuticals | 521.31M |
| Rhythm Pharmaceuticals | 189.76M |
| ImmunityBio | 113.29M |
| Kymera Therapeutics | 39.21M |
| Arcellx | 22.29M |
| Centessa Pharmaceuticals | 15.00M |
PTGX News
- 12 days ago - Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Accesswire
- 22 days ago - Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis - Accesswire
- 5 weeks ago - Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - Business Wire
- 6 weeks ago - CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Accesswire
- 6 weeks ago - Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Accesswire
- 6 weeks ago - Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026 - Accesswire
- 3 months ago - Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - Accesswire
- 3 months ago - Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) - Business Wire